Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline is a profitable and resilient company with a strong track record of success and a competitive advantage in the medical supply industry. Their strategic use of technology and expansion efforts, coupled with their strong financials and cash flow, demonstrate potential for further growth and success in the market. However, potential challenges such as competition and reliance on Prime Vendor agreements should be considered in evaluating the stock's potential.

Bears say

Medline is the largest medical-surgical products and supply chain solutions provider in the US, with significant scale, strong customer relationships, and vertically integrated manufacturing capabilities. However, the company's reliance on a single market and its high customer retention may limit future growth potential, while its heavy investments in manufacturing and logistics infrastructure may strain its financials. Despite its strong innovation and product pipeline, Medline may face challenges in competing with larger and more diversified competitors, jeopardizing its high margins and cash flow generation potential.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.